Navigation Links
University of Houston engineering professor awarded grant to study melanoma treatment
Date:4/26/2013

A University of Houston engineering professor has won a grant from the Melanoma Research Alliance to help develop one of the most promising therapies for patients with the disease.

Navin Varadarajan, an assistant professor of chemical and biomolecular engineering, received the Stewart Rahr-MRA Young Investigator Award. The grant gives him $225,000 over three years to study a therapy that has helped melanoma patients who aren't responding to any other treatment.

This treatment is a form of immunotherapy, an emerging field of medicine that involves engineering human immune cells to fight specific diseases. In particular, Varadarajan will study adoptive cell therapy (ACT).

ACT involves tumor-infiltrating lymphocytes (TIL), immune system cells that physically enter and then attack malignant tumors. In ACT, these cells are extracted from a patient and amplified in the lab. The stronger modified cells are then re-infused into the patient to facilitate the fight against his or her specific melanoma.

Early clinical trials using ACT to combat melanoma have been promising. Roughly 50 percent of patients have responded to the treatment, with some even going into complete remission.

"Essentially, ACT has become the last hope for survival for patients with melanoma that aren't responding to other conventional therapies," said Varadarajan.

Many other patients, however, don't respond to ACT at all. Understanding this huge gap in outcomes is the central goal of Varadarajan's research. The key to this work is a special polymer slide Varadarajan has developed dubbed the Nano well array. Instead of a flat surface, the slide has tens of thousands of individual chambers, each with a volume of about 50-100 pictoliters. At that size, the chambers are ideal for holding individual cells an incredibly valuable characteristic, said Varadarajan.

"One of the biggest challenges in biological research is studying individual cells. Standard slides are good for examining cell populations but they can't isolate specific cells. What the Nano well array does is shrink the container so that its dimensions are similar to those of a single cell. That lets us achieve single-cell resolution," he said.

In the first stage of this project, Varadarajan will study different sets of modified TIL cells that have not been injected into a patient. His goal will be to identify their specific properties involved in fighting tumors.

He will then take blood samples from ACT patients who have received identical sets of cells. Exposing these blood samples to the Nano well array, Varadarajan will then single out the engineered TIL cells among all the other cells. Notably, most of these TIL cells won't be those that were originally given to patients. Instead, they'll be the descendants of those first cells several generations removed, in fact.

After isolating and identifying these cells, Varadarajan will remove them from the array. He will then clone them by the million and study their cancer-fighting properties, paying special attention to how they have and haven't changed from the original engineered TIL cells. With all that done, he will match up the different cells with patient outcomes, helping to identify which ones have been the most successful in fighting different types of melanomas.

With this knowledge, researchers and physicians developing ACT for melanoma will be able direct their work toward the most promising treatments, hopefully speeding the development of successful new therapies that can even be targeted to individual patients.

"Immunotherapy is at the forefront of cancer treatment and research. In some cases it has actually resulted in complete remission," Varadarajan said. "To help the most people, though, we've got to understand exactly what properties of infused cells are most effective at fighting cancer. This research will help us quickly identify those properties so they can be included in the future rounds of research and clinical trials."

Varadarajan's collaborator/mentor on this project is Laszlo Radvanyi, professor of melanoma medical oncology research at the University of Texas MD Anderson Cancer Center. Additionally, Richard Willson, a chemical and biomolecular engineering professor at UH, will serve as the departmental mentor.

This is the third cancer research grant Varadarajan has won in recent months. He also received funding from the National Institutes of Health and the Cancer Prevention and Research Institute of Texas to conduct two separate studies on different immunotherapy-based treatments for lymphoma and leukemia.


'/>"/>

Contact: Laura Tolley
ljtolley@uh.edu
713-743-0778
University of Houston
Source:Eurekalert

Related biology news :

1. Saint Louis University, University of Toronto biologists help decode turtle genome
2. Wayne State University startup, Advaita, to participate in new Michigan I-Corps program
3. Indiana University associate professor earns APSs Henry Pickering Bowditch Award
4. University of Southern California scientists reveal natural process that blocks viruses
5. University of Houston engineering researchers theories to be tested in space
6. University of Tennessee professors research shows Gulf of Mexico resilient after spill
7. Mercyhurst Universitys new DNA sequencer to accelerate scientific research in region
8. Student named universitys first Lawrence scholar, researching at national laboratory
9. University of Tennessee professor links massive prehistoric bird extinction to human colonization
10. University of Montreal researchers discover how drug prevents aging and cancer progression
11. University of Californias unofficial favorite sea slug poised to make a comeback
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... For ... has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled ... Volunteer Experience from US2020. , US2020’s mission is to change the trajectory of ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
Breaking Biology Technology: